Breast Cancer Treatment Tablets For Osteoporosis.
The bone narcotic zoledronic acid (Zometa), considered a potentially positive weapon against breast cancer recurrence, has flopped in a novel study involving more than 3360 patients. The drug, long used to withstand bone loss from osteoporosis, did not appear to prevent breast cancer from returning or to boost disease-free survival overall fav-store.net. British researchers presented the pathetic findings Thursday at the San Antonio Breast Cancer Symposium in Texas.
And "As a whole, the learn is negative," study author Dr Robert Coleman, a professor of medical oncology at the University of Sheffield in England, said during a Thursday announcement forum on the findings panagara tablet in bangalore. "There is no overall difference in recurrence rates or survival rates between patients who got the bone slip and those who did not, except in older patients, defined as more than five years after menopause".
That was a possible shining spot in the results. "In that population, there is a benefit". The older women had a 27 percent change for the better in recurrence and a 29 percent improvement in overall survival over the five-year follow-up, compared to those who didn't get the drug.
And "There was tremendous count that this drug approach would be a major leap forward. There have been other trials that suggest this is the case". In one erstwhile study, the use of the drug was linked with a 32 percent progress in survival and lowered recurrence in younger women with breast cancer. Other research has found that salutary women on bone drugs were less prone to develop breast cancer, so experts were hoping the drugs had an anti-tumor effect.
Zometa, marketed by Novartis AG, is one of a breeding of drugs used to treat osteoporosis and also to sub for pain when cancers have spread to the bone - in part, by slowing bone erosion caused by the disease. It is given intravenously, while other bisphosphonates such as Actonel, Fosamax or Boniva can be infatuated orally.
